6628-83-7

Basic information

• Product Name: C-(TETRAHYDRO-PYRAN-2-YL)-METHYLAMINE HYDROCHLORIDE
• Synonyms: C-(TETRAHYDRO-PYRAN-2-YL)-METHYLAMINE;C-(TETRAHYDRO-PYRAN-2-YL)-METHYLAMINE HYDROCHLORIDE;TETRAHYDROPYRAN-2-YLMETHYLAMINE;TETRAHYDRO-PYRAN-2-YLMETHYLAMINE HCL;(TETRAHYDRO-2H-PYRAN-2-YL)METHANAMINE;2-aminomethyltetrahydro-pyra;2-aminomethyltetrahydropyran;2-(Aminomethyl)tetrahydro-2H-pyran
• CAS NO: 6628-83-7
• Molecular Formula: C₆H₁₃NO
• Molecular Weight: 151.63
• Product Categories: Amines and Anilines;API intermediates
• Mol File: 6628-83-7.mol

Chemical Properties

• Boiling Point: 211.9°C (rough estimate)
• Flash Point: 64.9°C
• Appearance: /
• Density: 1.0223 (rough estimate)
• Vapor Pressure: 0.912mmHg at 25°C
• Refractive Index: 1.4210 (estimate)
• CAS DataBase Reference: C-(TETRAHYDRO-PYRAN-2-YL)-METHYLAMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: C-(TETRAHYDRO-PYRAN-2-YL)-METHYLAMINE HYDROCHLORIDE(6628-83-7)
• EPA Substance Registry System: C-(TETRAHYDRO-PYRAN-2-YL)-METHYLAMINE HYDROCHLORIDE(6628-83-7)

Safety Data

• Statements: 41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 6628-83-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
C-(TETRAHYDRO-PYRAN-2-YL)-METHYLAMINE HYDROCHLORIDE is used as a reagent for the preparation of pharmaceutical intermediates, facilitating the synthesis of various therapeutic drugs.
It is particularly utilized in the production of antihistamines, contributing to the development of medications that counteract allergic reactions.
Additionally, it serves as a building block in the synthesis of complex natural products and other biologically active molecules, expanding its application in drug discovery and medicinal chemistry.

InChI:InChI=1/C6H13NO/c7-5-6-3-1-2-4-8-6/h6H,1-5,7H2

Upstream product

• 98435-78-0 (+/-)-tetrahydropyran-2-yl-acetic acid amide 
• 111293-46-0 2-(oxan-2-ylmethyl)-2,3-dihydro-1H-isoindole-1,3-dione 
• 181945-29-9 tetrahydropyranmethyl azide 

Downstream Products

• 100-72-1 Tetrahydropyran-2-methanol 
• 93545-84-7 6-hydroxyhexanal lactol 
• 1132671-64-7 (2S,4S,5S,7S)-5-azido-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (tetrahydro-pyran-2-ylmethyl)-amide 
• 1160508-19-9 3-tert-butyl-5-((cyclohexylmethyl)((tetrahydro-2H-pyran-2-yl)methyl)amino)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one 
• 1442119-79-0 (±)-4-methyl-N-(3,4,5,6-tetrahydro-2H-pyran-2-ylmethyl)-2-[(1-{4-[4-(trifluoromethyl)phenoxy]benzoyl}piperidin-4-yl)methyl]-2H-indazol-5-carboxamide 

Relevant articles and documents

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS

Certain 1H-imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolines, 1H-imidazo[4,5-c][1,5]naphthyridines, 6,7,8,9-tetrahydro-1H-imidazo[4,5-c][1,5]naphthyridines, and 1H-imidazo[4,5-c]pyridines substituted at the 1- and 2-positions, pharmaceutical compositions containing these compounds, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus

The first step in HIV infection is the binding of the envelope glycoprotein gp120 to the host cell receptor CD4. An interfacial "Phe43 cavity" in gp120, adjacent to residue Phe43 of gp120-bound CD4, has been suggested as a potential target for therapeutic intervention. We designed a CD4 mutant (D1D2F43C) for site-specific coupling of compounds for screening against the cavity. Altogether, 81 cysteine-reactive compounds were designed, synthesized, and tested. Eight derivatives exceeded the affinity of native D1D2 for gp120. Structure-activity relationships (SAR) for derivatized CD4 binding to gp120 revealed significant plasticity of the Phe43 cavity and a narrow entrance. The primary contacts for compound recognition inside the cavity were found to be van der Waals interactions, whereas hydrophilic interactions were detected in the entrance. This first SAR on ligand binding to an interior cavity of gp120 may provide a starting point for structure-based assembly of small molecules targeting gp120-CD4 interaction.

CB1 MODULATOR COMPOUNDS

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.